MenuClose
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter

Recent coverage

ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights

More tumor sites

Across disciplines

NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology

The 2026 program

The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.

Listen to Oncology Here & Now

The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.

Lung and thoracic videos

Round-ups and expert picks, newest first.

October 2025

  1. Day 3 round-up: the top five trials

    Dr. Gil Morgan. Daily round-up. ESMO 2025. Day 3.

  2. HARMONi-6, explained in Japanese

    Dr. Hidehito Horinouchi. Expert pick. ESMO 2025.

  3. Lung cancer: the picks from Berlin

    Dr. Biagio Ricciuti. Expert pick. ESMO 2025.

  4. HARMONi-6: ivonescimab in squamous NSCLC

    Dr. Hidehito Horinouchi. Expert pick. ESMO 2025.